ABOUT
About RX Ipamorelin.
An independent editorial project that summarizes the peer-reviewed ipamorelin literature — and nothing more.
What this site is
RX Ipamorelin is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on ipamorelin. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The data-forward angle of this digest leads with the body-composition record — lean mass, fat, IGF-1, and the GH pulse — because that is what most readers come looking for, and because it is where the gap between marketing and evidence is widest.
Is ipamorelin fda approved?
No. Ipamorelin is not approved by the FDA — or any regulatory authority — as a drug for any indication. It was investigated for postoperative ileus (NCT00672074) but the trial missed its primary endpoint and development did not proceed [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list and reviewed it at an October 2024 Pharmacy Compounding Advisory Committee meeting, restricting compounding-pharmacy access. It is sold only as a research chemical. This is precisely why the "rx" in this domain is editorial framing, not a medical claim.
On the 'rx' in the name
The "rx" in RX Ipamorelin is a positioning device, not a description of services. Ipamorelin is not a prescription drug; it has no approved indication and cannot be lawfully prescribed as an approved medicine. We state that plainly because it matters: a domain modifier like "rx," "clinic," or "doctor" reflects the editorial lens a publisher occupies relative to the literature — in our case, reading the research as if from a pharmacology desk — and never implies that this site prescribes, dispenses, or supplies anything. Nothing here is a prescription, a treatment plan, or an offer to sell.
How we handle the evidence
Every quantitative claim on this site is tied to a numbered citation drawn from the published literature, and the references page lists each source with its DOI or PubMed link. Where a study examined a related compound rather than ipamorelin itself — a GHRH analog like CJC-1295 or sermorelin, or a class-level safety agent — we say so in the text, so combination and class-level findings are never dressed up as ipamorelin-specific results. We describe what was measured, in which species, at which dose and route. We do not recommend human doses, and we do not promise outcomes the evidence has not earned.